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Abstract
Influenza virus infections yearly cause high morbidity and mortality burdens in humans, and the
development of a new influenza pandemic continues to threaten mankind as a Damoclean sword.
Influenza vaccines have been produced by using egg-based virus growth and passaging techniques that
were developed more than 60 years ago, following the identification of influenza A virus as an
etiological agent of seasonal influenza. These vaccines aimed mainly at eliciting neutralizing antibodies
targeting antigenically variable regions of the hemagglutinin (HA) protein, which requires regular
updates to match circulating seasonal influenza A and B virus strains. Given the relatively limited
protection induced by current seasonal influenza vaccines, a more universal influenza vaccine that
would protect against more—if not all—influenza viruses is among the largest unmet medical needs
of the 21st century. New insights into correlates of protection from influenza and into broad B- and
T-cell protective anti-influenza immune responses offer promising avenues for innovative vaccine
development as well as manufacturing strategies or platforms, leading to the development of a new
generation of vaccines. These aim at the rapid and massive production of influenza vaccines that
provide broad protective and long-lasting immunity. Recent advances in influenza vaccine research
demonstrate the feasibility of a wide range of approaches and call for the initiation of preclinical
proof-of-principle studies followed by clinical trials in humans.
Introduction
Seasonal influenza virus infections yearly cause three to
five million hospitalizations, resulting in 250,000 to
500,000 deaths worldwide [1]. Current vaccines against
seasonal influenza viruses offer protection from infec-
tion and disease caused by seasonal influenza viruses
closely related to those represented in the vaccines. Yet
they fail to provide broadly protective and long-lasting
immunity and they provide little or no protection
against so-called drift variants (see below) or zoonotic
influenza viruses that may be at the origin of rare but
devastating pandemics. Novel insights into the correlates
of protection against influenza virus infection and
disease and into broadly protective B- and T-cell
responses have been gained in recent years. Together
with the development of novel and innovative influenza
vaccine manufacturing strategies and platforms, they
offer promising avenues toward the generation of more
universal influenza vaccines.
Seasonal influenza is caused by influenza A and B viruses,
both belonging to the Orthomyxoviridae family [2].
Whereas influenza B viruses are principally human
pathogens, diverse influenza A virus (IAV) lineages are
maintained in a wide range of animal species, including
wild water birds, poultry, domestic swine, dogs, and
horses. Several of these animal IAVs can cause zoonotic
infections, with little or no onward transmission between
humans. Their further adaptation to humans may lead to
the development of a pandemic IAV, sweeping through
the human population. Four IAV pandemics have
occurred in the past 100 years, resulting in more than
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50 million deaths [3]. Following the pandemic they have
caused, pandemic viruses continue to circulate in the
human population as seasonal IAVs, after replacing one
of the previously circulating seasonal strains. Seasonal
IAVs may therefore be considered descendants of
pandemic viruses. They continuously evolve to escape
from antibody-mediated immunity in the human popu-
lation by accumulating mutations leading to so-called
antigenic drift. These changes, which occur predomi-
nantly in IAV surface glycoproteins—in particular the HA
protein—thus circumvent the neutralization of antigenic
drift variants by pre-existing antibodies. Because of this
continuous IAV evolution, regular updates of IAV vaccine
strains are required to match circulating IAV strains. A
more universal influenza vaccine that would not need
these periodic updates, but would give broad and long-
lasting immunity, is one of the largest unmet medical
needs of the 21st century. In the present article, we will
review the latest advances in our understanding of the
path that may eventually lead to amore universal vaccine
against influenza.
Correlates of protection
HA-specific neutralizing antibodies are recognized as a
major correlate of protection against IAV infection and
disease [4,5] (Fig. 1). These antibodies are induced upon
IAV infection and vaccination with current seasonal IAV
vaccines. Their induction is used as a primary correlate of
efficacy of classic non-live vaccines. They are typically
directed to epitopes in or in close proximity to the HA
receptor binding site, located in the globular head of
trimeric HA proteins [6]. By preventing the actual
binding of the HA proteins to their cellular receptors,
these antibodies efficiently neutralize IAVs. Both serum
immunoglobulin (Ig)Gs and secretory or mucosal IgAs
are efficient at inhibiting virus attachment and entry and
are induced upon vaccination with inactivated and live-
attenuated vaccines, respectively. At sufficiently high
titers, these antibodies can provide adequate immunity,
effectively protecting against infection or re-infection.
As mutations in HA antigenic sites are responsible for IAV
antigenic drift [6], resulting in antibody-escape variants
that can evade pre-existing immunity [4,5], current
seasonal IAV vaccines need regular updates in order to
induce neutralizing antibodies that match circulating IAV
strains. Furthermore, HA-specific neutralizing antibodies
offer no protection against infection with distantly related
IAVs or IAVs of different HA subtypes. Highly pathogenic
avian influenza virus (HPAIV) H5N1 and low pathogenic
avian influenza virus (LPAIV) H7N9 are currently at the
origin of large numbers of sporadic zoonotic infections
with little or no sustained transmission between humans
[7,8]. Should such viruses acquire the trait of efficient
transmissibility among humans, they may develop into
novel pandemic IAVs. Neutralizing antibodies against
today’s seasonal IAVs of the H1 and H3 subtypes would
offer little protection against such candidate pandemic
IAVs. Pandemic preparedness plans should therefore
include the development of pre-pandemic vaccines against
zoonotic IAVs that may eventually evolve into candidate
pandemic IAVs [9,10]. Given the level of antigenic drift in
these zoonotic IAVs, as for seasonal IAV vaccines, such pre-
pandemic vaccines may eventually offer too little protec-
tion against the newly emerging pandemic IAVs. To
increase the immunogenicity of currently available vac-
cines and obtain increased and broadened antibody
responses, the use of adjuvants can be considered an
integral tool of pandemic preparedness plans [11].
Although virus neutralization is considered the gold
standard in terms of correlates of protection from IAV
infection or influenza, antibodies that have no or poor
neutralizing activity may also confer a certain degree of
protection [12]. Protective antibodies directed to the other
IAV surface proteins, like the neuraminidase (NA) protein
and the ecto-domain of the matrix 2 protein (M2), have
widened the scope of potential IAV correlates of protection
[4,5] (Fig. 1). Because of the more conserved nature of the
epitopes involved, they hint at the possibility of inducing
broader immune responses, cross-reactive to a range of
antigenically distant IAV strains.
Protective effects of NA-specific antibodies have been
demonstrated in animal models since the late 1960s (see
references in [4]) and more recently in seroepidemiolo-
gical studies in humans [13-15]. Recently, monoclonal
antibodies targeting the conserved region of the NA
protein were shown to provide heterosubtypic protec-
tion in mice [16]. Because the NA protein is involved in
virus release from infected cells, NA-specific antibodies
may not provide sterilizing immunity but may limit
infection and disease severity. Specific antibodies against
the M2 ion-channel protein have also shown potential
for broad protection in animal models [17-30]. Although
such antibodies are not neutralizing and appear to be
produced in limited quantity upon infection, they may
contribute to antibody-dependent cellular cytotoxicity
(ADCC) mediated by natural killer (NK) cells and
thereby limit disease severity [24]. Seroprevalence of
antibodies targeting the M2 protein was recently shown
to increase with age in humans [31]. Moreover, the 2009
pandemic IAV H1N1 elicited a recall serum antibody
response against the M2 protein in some individuals.
The potential protective role of cellular immune
responses against IAVs has been increasingly recognized
in recent years (reviewed in [32]). Cellular immune
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correlates of protection may be particularly relevant for
novel antigenic variants or pandemic IAVs, when pre-
existing humoral immunity provides little protection.
Although they do not prevent re-infection, cytotoxic T
lymphocytes (CTLs) effectively limit infection and
disease severity (reviewed in [32]). Because CTL epitopes
are typically conserved, CTL responses also have the
potential to be broadly reactive, including against IAVs of
different subtypes. Evidence for cellular immune corre-
lates of protection in humans was recently indicated by
strong inverse correlations between pre-existing CD8+ T
lymphocyte populations and disease severity during the
influenza pandemic of 2009 [33].
Broadly protective immune responses
Because of the antigenic variability of the globular head
of the HA protein, the immune protection conferred by
neutralizing antibodies is typically highly specific to
circulating IAV strains and is short-lived. The evidence for
other correlates of protection, mediated by antibodies
directed to more conserved proteins or parts thereof and
by cellular immune responses directed to conserved
epitopes, raises hope for the development of broadly
protective influenza vaccines.
The potential for broadly reactive immune responses
against IAVs is further supported by the production of
broadly neutralizing antibodies directed to the HA stem
or other relatively conserved regions of the HA protein
(Fig. 1), by plasma cells of individuals infected with or
vaccinated against IAVs (reviewed in [12]). Although the
first broadly neutralizing and protective antibody against
IAV was discovered in the early 1990s in mice [34-36],
major advances in the recognition of such antibodies in
humans have occurred in the past six years. Broadly
neutralizing antibodies are directed to epitopes of either
the HA stem or the HA globular head [37]. Those
directed to the HA stem target conserved epitopes and are
generally broadly cross-reactive, recognizing IAVs of
different lineages and subtypes. Antibodies recognizing
IAVs belonging to the first IAV phylogenetic group
(comprising H1, H2, H5, H6, H8, H9, H11, H12, H13,
H16, and H17) are induced in many individuals infected
with or vaccinated against IAVs but typically remain
subdominant (reviewed in [12]). The HA globular head
is immunodominant and more immunogenic than the
HA stem in general, regardless of IAV strain or subtype.
The subdominant nature of broadly neutralizing anti-
body responses may result from limited accessibility of
HA stem epitopes closely packed on the viral membrane.
Antibodies recognizing IAVs belonging to the second IAV
phylogenetic group (comprising H3, H4, H7, H10, H14,
and H15) appear more rarely in humans. Antibodies
recognizing the stem region of the HA proteins of IAVs of
both phylogenetic groups as well as antibodies recogniz-
ing the HA stem of both IAVs and influenza B viruses
Figure 1. Antibody and cytotoxic T-cell epitopes on influenza A virus proteins
(A) Antibody epitopes are principally expressed on influenza A virus surface proteins: hemagglunitin (HA), neuraminidase (NA), and ecto-domain of matrix 2
(M2) ion-channel proteins. Epitopes located in the stem of the HA and in the NA and M2 proteins are typically conserved, inducing broadly neutralizing
antibodies (light blue antibodies). Epitopes located in the globular head of the HA are typically variable, leading to antigenic drift (targeted by dark blue
antibodies); exceptions may include conserved epitopes inside the receptor-binding pocket. (B) Cytotoxic T-cell epitopes are principally expressed on
influenza A virus internal proteins, notably the nucleoprotein (NP) and matrix 1 (M1) protein. They are processed and presented by antigen-presenting
cells via major histocompatibility complex (MHC) class I molecules.
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have recently been reported [38,39]. Broadly neutralizing
antibodies directed to the globular head may target the
relatively conserved region of the receptor-binding
pocket [12,37]. However, despite being strongly neu-
tralizing, these antibodies have usually a more limited
breadth of reactivity and can allow viral escape.
Because the HA inhibition assay currently used to
measure the human immune response to IAV does not
detect stem-specific antibodies, little is known about the
degree of protection conferred by broadly neutralizing
antibodies [12]. Other assays are available to detect such
antibodies and call for further research. Subdominant
broadly neutralizing antibody responses can become
dominant after heterologous boosting [5]. These anti-
bodies are known to efficiently bind to the less tightly
packed HA proteins expressed on the membrane of
infected cells. Recently, binding of these antibodies to Fc
receptors on effector cells, such as monocytes, macro-
phages, or NK cells, was shown to activate ADCC and to
provide protection in mice [40]. It suggests that
protection conferred by broadly neutralizing antibodies
may occur after viral entry, by recognition of HA stem
epitopes expressed on infected cells. At high doses,
however, these antibodies alsomediate neutralization of
viral binding, fusion, and entry [40]. It was recently
demonstrated that the majority of HA trimeric proteins
on intact 2009 pandemic influenza virions are available
to bind broadly neutralizing antibodies [41]. Thus,
protection conferred by broadly neutralizing antibodies
may occur via both virus neutralization and ADCC.
CD8+ CTLs are largely directed to epitopes within
conserved internal proteins, such as nucleoprotein (NP)
and matrix (M) proteins [32] (Fig. 1). These epitopes are
shared within and across IAV subtypes, contributing to
broad reactive responses. Although CTLs do not prevent
infection, they reduce virus replication and disease severity,
also in the absence of a detectable antibody response
(reviewed in [32]). Such protective effect may be particu-
larly relevant for heterosubtypic strains, such as antigenic
variants or pandemic IAVs, against which pre-existing
humoral immunity offers little protection. Protective
heterosubtypic immunity has mainly been demonstrated
in animal models and is indicated to play a role by
epidemiological studies in humans during past and most
recent pandemics [32,33]. Further evidence for protective
effects is indicated by selective pressure exerted by cellular
immune responses that can lead to immune escape
variants with amino-acid changes in CTL epitopes [32].
Some CTL epitopes are immunodominant, complicating
the analysis of CTL responses induced by infection or
vaccination. Efficient induction of CTL responses requires
endogenous antigen processing, their binding to major
histocompatibility complex (MHC) class I molecules, and
presentation by antigen-presenting cells (APCs) or infected
cells. The human leucocyte antigen (HLA) haplotype
determines the epitope on presentation and thus the
magnitude of CTL responses. Immunodominance, HLA
restriction, and antigen delivery to APC cytosol need to be
addressed by T cell-based vaccine formulations to induce
broad protective CTL responses [32]. Innovative vaccine
platforms increasingly aim at inducing such responses,
complementing induced humoral immunity.
Innovative vaccine platforms
Current vaccine formulations target three or four seasonal
influenza virus strains (IAVs H1N1 andH3N2) and one or
two (since 2013) influenza B virus strains [4,5,11,42].
Most conventional vaccines are subunit, split, or whole
inactivated preparations and are administered intramus-
cularly (Fig. 2). They induce virus neutralizing serum
antibody responses against the globular head of the HA
protein, when matching circulating strains. Adjuvants are
increasingly used to enhance and broaden immune
responses induced by inactivated vaccines. Theymodulate
the immune response, improve the immunogenicity of
the vaccine, and allow lowering of antigen loads. MF59
Figure 2. Range of current and new vaccine presentations against influenza A virus
Current vaccines against influenza A viruses are principally live attenuated, whole inactivated, split virion, and subunit vaccines. Among the new generation
of vaccines against influenza A viruses are subunit vaccines with carrier proteins acting as adjuvant (e.g. flagellin) and DNA plasmid and viral-vectored vaccines,
which target conserved regions of surface proteins or conserved internal proteins or both.
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and AS03 are oil-in-water emulsions currently used in
seasonal and pandemic vaccine formulations [11]. A
number of other adjuvants are in clinical evaluation. Live
attenuated vaccines (Fig. 2), administered topically in the
respiratory tract, induce good mucosal antibody
responses against the globular head of the HA protein
matching circulating strains, as well as CTL responses,
following uptake and processing by APCs. CTL responses
induced by these vaccines were shown to provide a certain
degree of heterosubtypic protection in mice [43,44]. Live
attenuated vaccines have been approved for marketing
and use in the United States and Russia [4] and, since
2011, in Europe [45].
Despite advances in the field, most vaccine formulations
continue to be produced by rather antiquated techni-
ques that have been in use for over 60 years and that
involve the growth and passaging of the vaccine strains
in embryonated chicken eggs [42]. Production and
subsequent formulation can take several months and
rely on the availability of embryonated chicken eggs.
Increasing demands for influenza vaccines, including
the need for rapid production of pandemic influenza
vaccines when a pandemic emerges, urgently require the
development of new egg-independent manufacturing
platforms. The first recombinant egg-free influenza
vaccine, produced in an insect cell line, was approved
by the US Food and Drug Administration in January
2013 and is available for the influenza season of 2013-
2014, demonstrating the feasibility of the concept [46].
Although debate and controversies are waging on
influenza vaccine efficacy and effectiveness, current
influenza vaccines provide beneficial protection against
seasonal influenza virus infection and disease, especially
for the elderly [47]. The degree of protection varies per
age group and per influenza season, depending in
particular on the strength and status of individual host
immune responses and underlying conditions and on
the level of match between influenza vaccines and
circulating strains [48]. Meta-analyses of randomized
controlled trials and observational studies to assess
influenza vaccine efficacy and effectiveness are a challen-
ging task, as many confounding factors may yield
erroneous conclusions. Although current vaccines do
not offer complete protection, they reduce the risk of IAV
infection and influenza-associated disease and death,
including in high-risk groups, such as young children
and the elderly [47]. Given the highly specific and rather
short-lived immunity they induce, they raise hope in
view of the significant improvements new and innova-
tive vaccine platforms may offer in the near future.
The next generation of influenza vaccines (Fig. 2), produced
in egg-independent manufacturing platforms, aim at
inducing more broadly reactive, long-lasting immunity
against a wide range of influenza virus types and subtypes
[4,5,11,42]. The selection of antigens as well as the antigen
delivery system used plays essential roles in enhancing,
broadening, and prolonging influenza virus-specific
immune responses. Conserved surface antigens, such as
epitopes in the NA andM2 proteins and in the stem region
of the HA protein, are interesting candidate antigens for
the induction of broad protective humoral immune
responses against IAVs. Both M2-based and stem-HA-
based vaccines have now been developed and tested in
animal models [19-30,49-58]. In a phase I clinical trial,
M2-based vaccines have proved relatively safe and immu-
nogenic in humans, although efficacy has yet to be
evaluated [59]. Adverse effects were observed following
injection of high doses, potentially mediated by cytokine
release. The expression ofM2 antigens in vectored vaccines,
co-expressed with the NP protein, or in combination with
an inactivated vaccine, also demonstrated heterosubtypic
protective effects in mice [28,30].
Stem-HA-based vaccines would currently be attractive
targets for the development of a more universal vaccine
and are under active research [42]. Their efficacy has been
shown to be promising in mice, ferrets, and non-human
primates. Large portions of the HA protein—including
the long alpha helix of the HA protein of IAVs belonging
to the second phylogenetic group [49,50], the HA2
portion of the protein [51], “headless” HA constructs
missing the immunodominant globular head of the HA
protein [52,53], and whole consensus HA proteins
[54,55]—have been used as conserved domains. Glob-
ular head constructs as well as chimeric HA constructs
that express both stem and globular head regions have
also been developed and proved efficacious in mice
[56,60]. These respective constructs were delivered to
experimental animal models in association with a carrier
protein, expressed on transfected cells, as DNA primes, or
via a viral vector. These vaccination schemes typically
elicited broadly neutralizing antibodies in the animal
models. Priming with DNA plasmids of a 2009
pandemic influenza virus H1N1 followed by boosting
with matched inactivated vaccine also induced broadly
neutralizing antibodies in animal models, including
non-human primates [57], and showed promising
results in a phase I clinical trial in humans [61]. Most
recently, self-assembling influenza nanoparticles expres-
sing HA trimeric proteins elicited broadly neutralizing
antibodies targeting both the HA stem and the receptor
binding pocket and protected ferrets against distantly
related IAVs [58].
In addition, a range of T cell-based vaccines have been
developed and tested in both animal models and phase I
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clinical trials in humans, offering additional avenues for
the induction of heterosubtypic immunity [32,42].
Targeted antigens are principally conserved internal
proteins, including NP and M proteins typically
expressed in combination with HA proteins either in
vaccine vectors, as DNA plasmids, or in particulate
formulations, such as immune stimulating complexes
(ISCOMs) and virosomes. Promising clinical trials in
humans have involved a Modified Vaccinia virus Ankara
(MVA)-based vaccine targeting influenza virus NP and
M1 proteins [62] and an epitope-based vaccine made of
an Escherichia coli expressed recombinant protein encod-
ing for HA, NP, and M1 epitopes [63].
The diversity of the approaches used in the above-
mentioned studies demonstrates the wide range of
options leading to avenues exploring the opportunities
of developing a universal influenza vaccine. This calls for
more preclinical proof-of-principle studies, the success-
ful completion of which should be followed by clinical
trials in humans.
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